About 10% of the patients had KRAS+/TP53+ NSCLC, whereas 18%, 36%, and 36% had KRAS+/TP53-, KRAS-/TP53+, and KRAS-/TP53- NSCLC, respectively. This evidence concerns the gene KRAS and non-small cell lung carcinoma.